Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
8450470 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Patent Drawings:Drawing: 8450470-15    
« 1 »

(1 images)

Inventor: Bookbinder, et al.
Date Issued: May 28, 2013
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Kosson; Rosanne
Assistant Examiner:
Attorney Or Agent: McKenna Long & Aldridge LLPSeidman; Stephanie
U.S. Class: 536/23.2; 435/201; 435/320.1; 435/325; 435/358; 435/69.1
Field Of Search: 536/23.2; 435/201; 435/320.1; 435/325; 435/69.1; 435/358
International Class: C07H 21/04; C12N 9/26; C12N 15/00; C12N 5/10; C12P 21/02
U.S Patent Documents:
Foreign Patent Documents: 1243948; 013420; 0822199; 01064951; 2311973; 6-153947; 6-503721; WO 88/02261; WO 88/09810; WO 89/10134; WO 90/11364; WO 92/06180; WO 92/16640; WO 92/20316; WO 92/22635; WO 93/14188; WO 93/20221; WO 94/08598; WO 94/28024; WO 96/31596; WO 98/16655; WO 98/52602; WO 99/02181; WO 99/29841; WO 99/32619; WO 00/02017; WO 00/66139; WO 01/87925; WO 01/55357; WO 01/76640; WO 01/29058; WO 02/49673; WO 2004/058147; WO 2004/078140; WO 2009/111066; WO 2009/117085; WO 2009/128917; WO 2009/128918; WO 2009/134380; WO 2010/077297
Other References:









Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
Claim: What is claimed:

1. A nucleic acid molecule, comprising a sequence of nucleotides encoding a hyaluronidase polypeptide, wherein: the nucleic acid molecule includes a stop codon, whereby theencoded hyaluronidase polypeptide is produced upon expression; and the encoded hyaluronidase polypeptide is selected from among: a polypeptide that consists of a sequence of amino acids selected from among amino acid residues 1-477, 1-478, 1-479, 1-480,1-481, 1-482, 1-483, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1; and a polypeptide that consists of a sequence of amino acids that contains amino acid substitutions in the sequence of amino acids set forth as 1-477, 1-478,1-479, 1-480, 1-481, 1-482, 1-483, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequenceidentity to a sequence of amino acids set forth as amino acid residues 1-477, 1-478, 1-479, 1-480, 1-481, 1-482, 1-483, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

2. The nucleic acid molecule of claim 1, wherein the encoded hyaluronidase polypeptide consists of a sequence of amino acids that contain amino acid substitutions in the sequence of amino acids set forth as 36-477, 36-478, 36-479, 36-480,36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity to a sequence of amino acids set forth as amino acid residues36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

3. The nucleic acid molecule of claim 1, wherein the sequence of nucleotides encodes amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

4. The nucleic acid molecule of claim 1, comprising the sequence of nucleotides set forth in SEQ ID NO:48.

5. The nucleic acid molecule of claim 1, comprising the sequence of nucleotides set forth as nucleotides 106-1446 of SEQ ID NO:6.

6. The nucleic acid molecule of claim 1, wherein: the encoded hyaluronidase polypeptide is selected from among: a polypeptide that consists of a sequence of amino acids selected from among amino acid residues 36-477, 36-478, 36-479, 36-480,36-481, 36-482 or 36-483 of SEQ ID NO:1; and a polypeptide that consists of a sequence of amino acids that contain amino acid substitutions in the sequence of amino acids set forth as 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ IDNO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity to a sequence of amino acids set forth as amino acid residues 36-477, 36-478, 36-479, 36-480,36-481, 36-482 or 36-483 of SEQ ID NO:1; and the nucleic acid molecule comprises a sequence of nucleotides encoding a signal sequence for secretion of the encoded polypeptide.

7. The nucleic acid molecule of claim 6, wherein the encoded signal sequence for secretion is an IgG kappa chain leader peptide.

8. The nucleic acid molecule of claim 7, wherein the IgG kappa chain leader peptide is encoded by the sequence of nucleotides set forth in SEQ ID NO:43.

9. A vector, comprising the nucleic acid molecule of claim 1.

10. The vector of claim 9, comprising the sequence of nucleotides set forth in SEQ ID NO:51.

11. The vector of claim 9 that is an expression vector.

12. The vector of claim 9 that is a eukaryotic vector.

13. The vector of claim 10 that is a Pichia vector, an E. coli vector, or a viral vector.

14. An isolated cell, comprising the vector of claim 9.

15. The cell of claim 14 that is a prokaryotic cell.

16. The cell of claim 14 that is a eukaryotic cell.

17. The cell of claim 14 selected from among a bacterial cell, a yeast cell, a plant cell, an insect cell and a mammalian cell.

18. The cell of claim 14 that is a Chinese hamster ovary (CHO) cell.

19. A method for producing a hyaluronidase polypeptide, comprising: (a) introducing the nucleic acid of claim 1 operably linked to a promoter into a cell capable of incorporating N-linked sugar moieties into the polypeptide; (b) culturing thecells in a suitable growth medium under conditions whereby an encoded hyaluronidase polypeptide is produced by expression of the introduced nucleic acid and secreted by the cell; and (c) recovering the expressed polypeptide.

20. The method of claim 19, wherein the cell is a eukaryotic cell.

21. The method of claim 20, wherein the eukaryotic cell is selected from a mammalian cell, an insect cell, a yeast cell and a plant cell.

22. The method of claim 20, wherein the cell is a Chinese hamster ovary (CHO) cell.

23. The method of claim 19, wherein the cells are cultured in the presence of 0.1-1 mM Sodium Butyrate under conditions suitable for production of the polypeptide.

24. The method of claim 22, wherein the cells are cultured in the presence of 0.1-1 mM Sodium Butyrate under conditions suitable for production of the polypeptide.

25. A vector, comprising the nucleic acid molecule of claim 4, or degenerates thereof.

26. A vector, comprising the nucleic acid molecule of claim 5, or degenerates thereof.

27. A nucleic acid molecule, comprising a sequence of nucleotides encoding a hyaluronidase polypeptide, wherein: the nucleic acid molecule includes a stop codon, whereby the encoded hyaluronidase polypeptide is produced upon expression; andthe encoded hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% amino acid sequence identity to the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1.

28. A vector, comprising the nucleic acid of claim 27.

29. The vector of claim 28 that is a Pichia vector, an E. coli vector, or a viral vector.

30. An isolated cell, comprising the vector of claim 28.
Description:
 
 
  Recently Added Patents
Methods of enhancing diabetes resolution
Method for the hydrolysis of substituted formylamines into substituted amines
Single mode optical fiber with improved bend performance
System and method for employing signoff-quality timing analysis information concurrently in multiple scenarios to reduce dynamic power in an electronic circuit and an apparatus incorporating t
Method and apparatus for storing email messages
Systems and methods for arranging and labeling cardiac episodes
Method and system for triggering message waiting indicator delivery
  Randomly Featured Patents
Method of manufacturing an electro-magnetic deflection unit for a cathode ray tube
Signal system for vehicles
Skin care formulations
Hair clip
Multi-phase clock system
System and method for management of a ground obstacle display
Seat back structure of vehicle seat
Gear train of automatic transmission for vehicles
Chemically treated filters
Architecture for a semiconductor memory device for minimizing interference and cross-coupling between control signal lines and power lines